SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the implications of the company's recent Phase III trial failure for its Alzheimer's drug, with some investors expressing disappointment while others see it as an opportunity to buy. Despite the setback, there is optimism surrounding Novo Nordisk's position in the weight loss market, particularly with the potential upcoming approval of its oral Wegovy pill and comparison of CagriSema vs Zepbound study results.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid mixed sentiment, as discussions range from its ties to controversial figures to its evolving stance on cryptocurrency and potential competition with Bitcoin. The community is actively debating JPMorgan's investment strategies, alleged market manipulation, and the implications of its exploration of blockchain technology and stablecoins. Additionally, some traders are monitoring technical indicators to predict JPM's short-term price movements, while others are discussing potential investigations and regulatory scrutiny.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is trending due to news of expanded robotaxi operations and partnerships, including a recent permit in Shanghai. The community is weighing the company's growth prospects against its financial performance, especially regarding profitability targets. Broader discussions involve comparing Pony AI to competitors in the autonomous driving space and assessing the impact of these developments on its market position.

Monad

Monad is trending as users discuss its upcoming launch and token distribution, particularly excitement around receiving tokens from the Coinbase presale. The community is actively speculating on potential price movements and strategies, with some comparing it to other recent launches. There's also discussion around the mainnet launch date.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to strong Q3 2025 earnings, highlighted by a 144.3% YoY revenue increase and significant growth in robotaxi revenue, with community members noting global expansion and regulatory milestones in the UAE and Switzerland. Investors are focused on WeRide's progress toward deploying hundreds of thousands of robotaxis by 2030 and its partnerships with companies like Bosch, Uber, and Grab. The conversation also includes comparisons to competitor Pony.ai, whose stock performance and institutional ownership are being weighed against WeRide's recent gains and expansion efforts.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid uncertainty surrounding the Affordable Care Act (ACA) subsidies, with discussions focusing on potential impacts from Trump's healthcare proposals. The community is weighing the company's prospects with or without the subsidies, while some highlight Oscar Health's cash position and potential for growth in individual health plans. Options traders are active, with both bullish call buying and bearish put buying strategies being discussed.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending following the announcement of European approval for AVT03, a biosimilar to Prolia and Xgeva, used in bone disease treatment, sparking bullish sentiment. Despite some community concerns about cash flow and previous manufacturing setbacks, the biosimilar's approval and analyst upgrades are fueling optimism. Discussions center on the company's potential in the biosimilar market and strategic partnerships.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is gaining attention, with community members highlighting recent updates and increased market interest. The community emphasizes the project's potential, strong fundamentals, transparent communication, and clear utility development, with some anticipating significant growth. Discussions also touch on the token's low market cap, growing holder base, and potential for a breakout, particularly within the Solana ecosystem.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi-Aventis ($SNY) is trending amid speculation surrounding potential acquisitions, particularly in the MASH and obesity spaces, with $ALT, $GUTS, and $IVA being mentioned as possible targets. Community discussions revolve around the company's pipeline expansion needs and potential partnerships, with some users highlighting data integrity concerns around one of the speculated targets. The broader context involves Sanofi's strategic moves to strengthen its immunology and vaccine portfolio.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Bayer said its new Phase III stroke study of asundexian hit both primary efficacy and safety goals.</li><li>The update comes two years after the company halted the OCEANIC-AF trial when interim data showed asundexian was inferior to Eliquis.</li><li>The study enrolled more than 12,300 patients worldwide, and Bayer plans to engage with regulators as it prepares marketing submissions.</li></ul><p>Retail traders turned hyper bullish on Sunday after Bayer AG confirmed that its Phase III stroke study of asundexian met its primary efficacy and safety endpoints, two years after the company halted its separate OCEANIC-AF trial in 2023.&nbsp;</p><h2 class="st-heading-2"><strong>Asundexian Reduces Ischemic Stroke Risk&nbsp;</strong></h2><p>Bayer said patients taking 50 mg of asundexian once a day alongside antiplatelet therapy saw a meaningful drop in ischemic stroke risk compared with those given a placebo and antiplatelet therapy. The company added that the treatment did not lead to higher rates of major bleeding. Bayer said this is the first late-stage study of a drug in the Factor Xla inhibitor class, which helps prevent clots from forming, to be successfully completed.</p><h2 class="st-heading-2"><strong>Large Global Phase III Study&nbsp;</strong></h2><p>Bayer said the trial was&nbsp;conducted across multiple countries and medical centers, using a randomized, placebo-controlled design. More than 12,300 patients took part, all of whom had recently experienced a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The study tested whether adding asundexian to standard antiplatelet therapy could lower their chances of having another stroke.</p><h2 class="st-heading-2"><strong>High Burden Of Recurrent Strokes</strong></h2><p>The company noted the growing global need for better secondary stroke prevention. They said nearly 12 million people worldwide experience a stroke each year, and that 20%–30% are recurrent. One in five stroke survivors will have another stroke within five years, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk.</p><p>Mike Sharma, MD, principal investigator of OCEANIC-STROKE, said the topline results indicate that asundexian may become a new treatment option for reducing recurrent stroke risk.&nbsp;</p><h2 class="st-heading-2"><strong>Regulatory Path&nbsp;</strong></h2><p>Bayer said it will now engage with health authorities globally as it prepares to submit marketing authorization applications. Asundexian has Fast Track Designation from the U.S. Food and Drug Administration for stroke prevention in patients after a non-cardioembolic ischemic stroke. Bayer said asundexian remains investigational and is not approved in any country.</p><h2 class="st-heading-2"><strong>Halt Of OCEANIC-AF After Inferiority To Eliquis</strong></h2><p>Asundexian drew attention in 2023 when Bayer halted its OCEANIC-AF Phase III trial. Interim findings showed the drug did not perform as well as Eliquis, made by Bristol-Myers Squibb and Pfizer, in preventing strokes in high-risk atrial fibrillation patients. Bayer said the safety profile matched earlier studies and noted that independent trial supervisors advised continuing the stroke-focused OCEANIC-STROKE study.</p><p>Bayer said asundexian is part of the factor XI inhibitor drug class, which has also drawn interest from Novartis working with Blackstone, and from Bristol-Myers Squibb working with Johnson &amp; Johnson. The compound had been positioned as one of four new drug hopefuls Bayer said carried a combined peak sales potential of more than 12 billion euros. The program followed the company’s Xarelto blood thinner franchise, which is expected to lose protection from key European patents in 2026.</p><h2 class="st-heading-2"><strong>Stocktwits Mood Turns ‘Extremely Bullish’</strong></h2><p>On Stocktwits, retail sentiment for Bayer was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:970/142;" src="https://news.stocktwits-cdn.com/bayer_ss_png_e2cb5716df.webp" alt="bayer ss.png" width="970" height="142"><figcaption>BAYRY sentiment and message volume as of November 23 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/BAYRY">Bayer’s U.S.-listed stock</a> has risen 63% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Signage and the building of the Bayer AG pharmaceutical and biotechnology company are seen at one of its industrial sites in Wuppertal, North Rhine-Westphalia, Germany. (Photo by Michael Nguyen/NurPhoto via Getty Images)

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt

The update comes two years after the company halted the OCEANIC-AF trial when interim data showed asundexian was inferior to Eliquis.

Equity

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth

Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.

REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD

Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion. 



BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU 

Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms

RHHBY Reports Positive Phase III Data on Breast Cancer Drug 

Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains 

Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.



Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales 

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.

Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?

Here is how Medpace (MEDP) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase 

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand. 

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

BAYRY
Bayer AG (ADR)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BAYRY News

BAYRYBayer AG (ADR)